CDS2 Activators are a category of chemical compounds known for their ability to influence the activity of the CDS2 enzyme, an integral player in phospholipid biosynthesis. This enzyme catalyzes the conversion of phosphatidic acid to CDP-diacylglycerol, a pivotal step in the phospholipid generation pathway, which is crucial for maintaining cellular integrity and functionality.
The list of chemicals associated with CDS2 activation includes diverse molecules, each with distinct mechanisms. Insulin, for instance, promotes lipid synthesis, which can in turn augment CDS2 activity, ensuring the necessary phospholipids are generated. Similarly, diacylglycerol (DAG) levels, when elevated, can indicate a cellular need for its conversion to phosphatidic acid, pushing CDS2 into action. On the signaling front, molecules like U0126 inhibit MEK, an upstream regulator of ERK. Given ERK's involvement in lipid metabolism, its modulation can exert downstream effects on CDS2. Similarly, LY294002, a PI3K inhibitor, acts upon the PI3K/AKT pathway, a significant regulator of diverse cellular processes, including lipid metabolism. Chemicals like Rosiglitazone and WY-14643 serve as activators for PPARγ and PPARα respectively. Both PPAR variants control genes tied to lipid metabolism, implying an indirect effect on CDS2 activity. Another critical metabolic regulator, AMPK, which can be activated by compounds like Metformin and AICAR, plays a role in energy metabolism, influencing lipid pathways and, by extension, CDS2. Lastly, chemicals such as Lovastatin and Sphingosine-1-phosphate, respectively influencing cholesterol synthesis and phospholipid signaling.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Insulin | 11061-68-0 | sc-29062 sc-29062A sc-29062B | 100 mg 1 g 10 g | $153.00 $1224.00 $12239.00 | 82 | |
Insulin can promote lipid synthesis and may enhance the activity or expression of enzymes like CDS2. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
mTOR signaling plays a role in lipid metabolism. Its inhibition might indirectly upregulate CDS2 to compensate. | ||||||
1,2-Dioctanoyl-sn-glycerol | 60514-48-9 | sc-202397 sc-202397A | 10 mg 50 mg | $46.00 $249.00 | 2 | |
Elevated DAG levels can suggest a need for conversion to phosphatidic acid, potentially increasing CDS2 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
PI3K inhibitor. The PI3K/AKT pathway regulates many cellular processes including lipid metabolism. | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $118.00 $320.00 $622.00 $928.00 $1234.00 | 38 | |
A PPARγ agonist. PPARγ controls lipid metabolism genes, potentially influencing CDS2 activity. | ||||||
WY 14643 | 50892-23-4 | sc-203314 | 50 mg | $133.00 | 7 | |
PPARα activator. PPARα, like PPARγ, is involved in lipid metabolism and might affect CDS2. | ||||||
Fenofibrate | 49562-28-9 | sc-204751 | 5 g | $40.00 | 9 | |
Another PPARα activator influencing lipid metabolic pathways, potentially impacting CDS2. | ||||||
Metformin-d6, Hydrochloride | 1185166-01-1 | sc-218701 sc-218701A sc-218701B | 1 mg 5 mg 10 mg | $286.00 $806.00 $1510.00 | 1 | |
AMPK activator. AMPK plays a key role in energy metabolism, potentially affecting lipid pathways and CDS2. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $60.00 $270.00 $350.00 | 48 | |
Another AMPK activator with potential effects on lipid metabolism and thereby possibly on CDS2. | ||||||
Lovastatin | 75330-75-5 | sc-200850 sc-200850A sc-200850B | 5 mg 25 mg 100 mg | $28.00 $88.00 $332.00 | 12 | |
HMG-CoA reductase inhibitor affecting cholesterol synthesis, potentially having an indirect effect on CDS2. | ||||||